Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
one more after-hours. DYAX.
PFE. Pfizer’s XALKORI® Receives Conditional Marketing Authorization from the European Commission for the Treatment of Adults with Previously Treated ALK-Positive Advanced Non-Small Cell Lung Cancer in the EU
http://finance.yahoo.com/news/pfizer-xalkori-receives-conditional-marketing-150000551.html
After-hours iBoxed. FLR.
Poem Stone-- thanks for nooner in I Box! Many thanks!!
'Nooner' iBoxed. GFF.
Nice looking chart- will be out most of today.- fwiw
Akrx---- thanks for the heads up about launch of Prometrium! I appreciate it a lot!
RGEN. Regeneron Reports Third Quarter 2012 Financial and Operating Results
-- Third quarter EYLEA® (aflibercept) Injection sales increased 26% over second quarter to $244 million
-- Full year 2012 EYLEA U.S. sales forecast increased from $700 - $750 million to $790 - $815 million
-- Third quarter non-GAAP profit climbs to $217 million or $1.89 per diluted share
http://finance.yahoo.com/news/regeneron-reports-third-quarter-2012-103000608.html
Another bouncer(?) ALXN. 6:30am. non-GAAP net income of $120.7 million, or $0.60 per share, in the third quarter of 2012, compared to non-GAAP net income of $72.6 million, or $0.37 per share, in the third quarter of 2011.
http://ih.advfn.com/p.php?pid=nmona&article=54667172
AKRX. Akorn Announces the Approval and Launch of Generic Prometrium®
http://finance.yahoo.com/news/akorn-announces-approval-launch-generic-100000961.html
Big Board Bios.
[StocksDiva]
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=80825488
The Resolute drug-eluting stent from Medtronic, Inc. (NYSE: MDT) delivered successful clinical results, according to new data presented at the 24th Annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium for the treatment of long lesions and small vessels -- two challenging characteristics of coronary artery disease commonly found in patients with diabetes.
"The Resolute stent continues to provide consistent and favorable clinical results," said Ronald Caputo, M.D., director of cardiac services and cardiology research at St. Joseph's Hospital in Syracuse, N.Y. "Patients with long lesions and small vessels are among the most difficult to treat, and for those who also have diabetes it can be even more challenging."
Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG) announced its phase III, multi-center, randomized, open-label study (MM-003) of pomalidomide plus low-dose dexamethasone compared to high-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma was reviewed by a data safety monitoring board (DSMB). The DSMB determined MM-003 met the primary endpoint of improvement in progression-free survival (PFS) at the PFS final analysis. Additionally, at the OS interim analysis, the study crossed the superiority boundary for overall survival (OS), a key secondary endpoint that the study was also powered to evaluate. Improvements in PFS and OS were both highly statistically significant and clinically meaningful. As a result, the DSMB recommended that patients who had not yet progressed in the high-dose dexamethasone arm should be crossed-over to the pomalidomide plus low-dose dexamethasone arm.
Safety results observed in MM-003 were consistent with previous studies of pomalidomide in relapsed/refractory multiple myeloma patients. Full data from the study are being prepared for submission to a future medical meeting for presentation.
“The survival results in this study build on earlier observations of high response rates for pomalidomide and dexamethasone in multiple myeloma patients who had been exposed to multiple therapies, including immunomodulatory agents and proteasome inhibitors,” said Dr. Jesus San Miguel, Head of the Department of Hematology at the University of Salamanca, Director of the Biomedical Research Institute of Salamanca and principal investigator in the study. “The continued progress of new agents in this area of disease, particularly in later-stage patients is critical as we look to extend remissions and survival for these individuals.”
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it will host a conference call and live webcast to report its third quarter 2012 financial results on Tuesday, October 30 at 8:30 a.m. ET.
Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the first quarter of fiscal 2013 on Monday, October 29, 2012, and will hold a conference call on Tuesday, October 30, 2012 at 9:00 a.m. eastern time to discuss these results.
AstraZeneca and Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today an agreement to co-develop and co-commercialize Ironwood’s linaclotide in China. Linaclotide is the first and only guanylate cyclase-C (GC-C) agonist approved by the US Food and Drug Administration, in August.
AVEO Oncology (NASDAQ: AVEO) today announced that financial results for the company’s third quarter ended September 30, 2012 will be released before the market opens on Tuesday, October 30, 2012.
Boston Scientific Corporation (NYSE: BSX) further demonstrated the strength of its structural heart program today at the 24th Annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation with four podium presentations showcasing the potential of the WATCHMAN® Left Atrial Appendage Closure (LAAC) Device and the Lotus™ Aortic Valve System to provide improved treatment options for millions of patients experiencing debilitating heart disorders.
Bovie Medical Corporation (the “Company”) (NYSE Amex: BVX), a manufacturer and marketer of electrosurgical products, today announced that Jeff Rencher, Vice President of Sales and Marketing of Surgical Products, will host a conference call at 11:00 am EDST on Thursday, November 1st to discuss Bovie’s J-Plasma technology.
Compugen Ltd. (NASDAQ: CGEN) today announced that the Company will host a conference call at 10:00 AM EDT on Tuesday, October 30, 2012 to review third quarter 2012 results.
Cytori Therapeutics (NASDAQ: CYTX) today announced that an investigator-sponsored and funded clinical study evaluating Cytori’s cell therapy as a potential treatment for limited and diffuse cutaneous systemic sclerosis (scleroderma) has been approved to begin in France by the National Agency for the Safety of Medicines and Health Products (ANSM, formerly AFSSAPS).
Elan Corporation, plc (“Elan”) (NYSE: ELN) announced today the expiration and final results of the cash tender offer and consent solicitation (the “Tender Offer and Consent Solicitation”), commenced on September 24, 2012, by its wholly-owned subsidiaries, Elan Finance public limited company (“Elan Finance”) and Elan Finance Corp. (“Elan Corp.” and together with Elan Finance, the “Co-Issuers”), to purchase any and all of their outstanding 8.75% Senior Notes due 2016 issued on October 2, 2009 (the “2009 Notes”) and 8.75% Senior Notes due 2016 issued on August 17, 2010 (the “2010 Notes” and, together with the 2009 Notes, the “Notes”).
Given Imaging Ltd (NASDAQ: GIVN), a world leader in GI medical devices and pioneer of capsule endoscopy, today announced new studies underscoring the value of PillCam® SB in identifying and evaluating small bowel abnormalities.
Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG) (the “Company”), the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced the Company will be presenting a poster at the upcoming American Society of Nephrology’s Kidney Week 2012, taking place from October 30 to November 4 in San Diego.
Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions and cellular-based virology assays, announced today financial results for the third quarter ended September 30, 2012.
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that it has expanded its antibody-drug conjugate (ADC) collaboration with Abbott (NYSE:ABT).
Sigma-Aldrich (NASDAQ: SIAL) Reports Q3 2012 Diluted EPS Of $0.92 And Diluted Adjusted EPS Of $0.94. Sales Increased 2% For Q3 2012. Reaffirms Full Year 2012 Adjusted Diluted EPS Of $3.80 to $3.90.
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of synthetic biologics and innovative medicines for serious diseases and unmet medical needs, announced today that Andrew Bristol, Ph.D., joined the team as its new Vice President of Research & Development.
Techne Corporation's (NASDAQ: TECH) financial results for the quarter ended September 30, 2012 .
United Therapeutics Corporation (NASDAQ: UTHR) announced today that it received a complete response letter from the United States Food and Drug Administration (FDA) declining to approve its new drug application (NDA) for treprostinil diethanolamine extended release tablets (oral treprostinil) for the treatment of pulmonary arterial hypertension (PAH).
Verastem, Inc., (NASDAQ: VSTM) a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced the appointment of Joanna Horobin, M.B., Ch.B., as Chief Medical Officer.
FoxBusinessNews/video Apple’s Big Unveil of Mini iPad
http://video.foxbusiness.com/v/1920102544001/
Welcome glassy as a moderator.
FB~ I kept my 19.60 short position now 19.42. Look at this- wow
http://finance.yahoo.com/news/zynga-apparently-just-laid-off-181131472.html
Zynga apparently just laid off over 100 employees, TechCrunch reports
Theflyonthewall.com – 10 minutes ago.. .
Digital game maker Zynga (ANGA) just laid off over 100 employees from its Austin office, according to TechCrunch, which cited Justin Maxwell, a former Apple (AAPL) and Smule employee. The laid off Zynga employees worked on the company's Bingo and TheVille teams, and were given just two hours to clean out their desks, the website added.
NK- our oldest son lived on the 3rd floor apt a few years back and I could NOT imagine as there was no elevator of course.- ha ha! laundry, groceries...ugh!
AMRN. Amarin Announces Issuance of U.S. Patents 8,793,727 and 8,293,728 for Vascepa(TM)
Issuances for '889 and '153 Applications
http://finance.yahoo.com/news/amarin-announces-issuance-u-patents-113000571.html
CTRX. Catamaran Announces $60 Million in Contracts with State of Indiana Medicaid
http://finance.yahoo.com/news/catamaran-announces-60-million-contracts-110000048.html
no iHub board.
glassy. I love having the elevator work!
Oh man....
1st couple of days I walked up the stairs doorway
next to it at least once.
It had been down since July 23rd.
Big expense for a non for profit.
Don't know where the money came from.
from [MiamiGent]. PGRX. A PR at midnight.
Prospect Global Resources and Sichuan Chemical Sign $2-Billion-Plus, 10-Year Purchase and Sale Agreement for Potash
http://ih.advfn.com/p.php?pid=nmona&article=54628599
WPI. Watson Receives Favorable Court Decision Regarding Generic Actos® Approval
- Court Instructs FDA to Approve Watson's ANDA -
http://finance.yahoo.com/news/watson-receives-favorable-court-decision-220800155.html
Our elevator at work has been fixed.
It went down with a computer problem July 23rd.
We have only 3 floors including the basement
(an old bank vault) where I work. Main office, 3rd floor.
We all got used to using the stairs.
Man! what a luxury.
It is a wonderful thing.
that was "SIR, YES SIR!"
Very nice. Thanks glassy.
Is that 3 days gapped in a row? woW. AONE.
AONE~ UP 56% at .1942
SATC~ UP 50% at .3799
AONE~back in at .18! I want it to break .20 now... .1936
Indian Fever WNBA Champions.
http://www.examiner.com/article/tamika-catchings-leads-indiana-fever-to-long-awaited-wnba-championship
NDIANAPOLIS – The final piece of the puzzle in Tamika Catchings’ Hall of Fame career has come into place. She is a WNBA champion.
Catchings scored 25 points and dished eight assists Sunday as her Indiana Fever captured its first-ever WNBA title with an 87-78 victory over the Minnesota Lynx in Game Four of the Finals in front of a sellout crowd of over 15,000 that included her college coach Pat Summitt.
The three-time Olympic gold medalist, two-time World champion and NCAA champion was named MVP of the Finals, averaging 22.3 points, six rebounds and 3.5 assists, adding that superlative to her 2011 regular season MVP, 2000 NCAA Player of the Year award, and five Defensive Player of the Year awards.
“This journey has been full of ups and downs,” the 33-year-old Catchings said, “full of trials and tribulations, full of tears and happy faces. But today we stand with happy faces, and I like that.”
The Fever lost to the Phoenix Mercury in five games in 2009, its only other Finals appearance.
It not only was the first title for Catchings, but for Katie Douglas and Tammy Sutton-Brown, who have also played 12 seasons in the league with multiple All-Star selections.
The defending champion Lynx, who opened the season 10-0 and finished with the league’s best record of 27-7, failed in its attempt at being the first repeat champions since the 2001-02 Los Angeles Sparks.
“It was hard being the hunted,” Lynx coach Cheryl Reeve said. “There’s a reason this hasn’t been done in over 10 years. I really felt like if there was a team that could do it, it was our team because we have tremendous resolve and great people that are unselfish, and those are really key ingredients.”
Erin Phillips added 18 points, while Shavonte Zellous and Arizona State alumna Briann January both scored 15 for the Fever. Erlana Larkins controlled the boards again for Indiana with 13 rebounds, Lindsay Whalen finished with 22 points and eight assists, and Maya Moore scored 16 for the Lynx.
Phillips scored seven of the Fever’s first 11 points, and Indiana would double up on Minnesota early, 18-9. The Fever was up seven, 25-18, after one.
“We came out with a lot of lot of adrenaline, and I felt the momentum carried over from Friday’s game,” Catchings said. “We came out knowing from a defensive standpoint, we needed to jump on them straight from the beginning, offensively just sharing the ball.”
In the second quarter, the Lynx began closing the gap, with Lindsay Whalen cutting the lead to one midway through. Rebekkah Brunson tied it at 38-38 with 3:30 to go and again at 40-40 two minutes later. Catchings drained two free throws, and Jessica Adair knotted it at 42-42 with a little over a minute left. However, Catchings would hit a three, and January scored to put Indiana up five at the break. Whalen led all with 14 points, and Catchings and Phillips both had 13.
Catchings came out of halftime hot, scoring a three 30 seconds in to put her team up eight, and the lead increased to 10 after her seventh point of the first three minutes. The Lynx would answer with an 8-0 run in the next two minutes, capitalized with a beautiful Maya Moore layup. She tied it at 56-56 with a similar play two and a half minutes later, only to be answered with a dead-on Catchings three. Catchings then picked off Whalen on the other end, and Jessica Davenport made it 61-56 in the post.
A Karima Christmas three put the Fever back up six in the fourth quarter, but Erin Thorn halfened that lead with one of her own on the ensuing Lynx possession. A Shavonte Zellous three from the corner soon put the Fever back up eight with five minutes remaining.
After a timeout with 1:10 left, January found the bottom of the rim on a three again and would sink four free throws with 19.7 and 3.2 seconds to seal the deal. Fever coach Lin Dunn then inserted Katie Douglas at 3.2 to a rousing ovation from the crowd, the only three seconds she would see in the series after suffering a sprained left ankle in the Eastern Conference Finals.
“I just thought Catchings and January and Larkins and Erin Phillips and Z (Shavonte Zellous) were on a mission,” Dunn said, “and I don’t know if Katie being hurt further motivated them or not, but they were just amazing this whole series.”
There were so many players on the Fever roster who had this moment coming to them for a long time.
Douglas is a four-time All-Star and five-time member of the All-Defensive Team after winning the 1999 NCAA title at Purdue.
Toronto native Sutton-Brown played in two All-Star Games, led Rutgers to the 2000 Final Four (losing to Catchings’ Tennessee team), and represented Canada in the 2000 Sydney Olympics.
Phillips, who won the silver medal for Australia in Beijing, was cut from the Olympic team this year.
January, who played for the Sun Devils from 2005-09 and led them to two Regional Finals, joined Catchings on the WNBA All-Defensive Team this year after missing the final 24 games of 2011 with an ACL tear.
“We said it day after day, we had to be in attack mode,” January said. “We had to keep pressuring them; we had to make them uncomfortable; and we had to focus on our game. If we did what we needed to do, rebound, attack, play our kind of defense, we were going to make it tough for them.”
January limited Seimone Augustus to 3-of-21 shooting and eight points Sunday, two days after she scored six points in Game Three.
It was a banner year for Moore, Augustus, and Whalen, winning the gold in London with Catchings. For the often-ringed Moore, her season ends on the same court where she lost in the 2011 Final Four, the only other event she has failed to win since her freshman year at Connecticut.
“We’re really proud of what we’ve accomplished, and it doesn’t take anything away from how special this group is,” Moore said of the Lynx.
Taj McWilliams-Franklin, the Lynx’s 42-year-old center, played in her 17th career Finals game, moving her into first all-time. Her teammate, Brunson, moved into a tie with Swin Cash, Deanna Nolan and Elaine Powell for second at 16 games.
The Fever became the first Eastern Conference team other than the Detroit Shock to win the title, which was last accomplished in 2008. The Shock now plays in Tulsa in the Western Conference, thus, the Fever is the only current franchise of the six in the East to own a trophy.
DSCI. Derma Sciences on Track to Begin Phase 3 Program with DSC127 in December Following Meeting with FDA
http://finance.yahoo.com/news/derma-sciences-track-begin-phase-113000927.html
OREX. Orexigen Therapeutics Receives Dispute Response Indicating FDA is Highly Supportive of Exploration of a Faster Path to Resubmission of the Contrave NDA
-- Light Study enrollment surpasses 7,000 patients; the Company plans to continue enrollment to approximately 9,000 patients by year end, speeding the time to interim analysis
http://finance.yahoo.com/news/orexigen-therapeutics-receives-dispute-response-110200473.html
WSJournal. Dean, Marathon Split-Offs on Tap
http://on.wsj.com/PLYSxV
NEW YORK—Three IPOs are expected to reach the market in the coming week, with two of those arriving as split-offs from existing public companies—dairy company Dean Foods Co. DF +2.01% and refiner Marathon Petroleum Corp.
Dean, the largest U.S. dairy producer by revenue, will carve out its higher-margin organic and soy business into an independent company with the initial public offering of WhiteWave Foods Co., expected Friday.
Dean, based in Dallas, will sell 20 million WhiteWave shares to help pay down existing debt, creating new common stock for the maker of Horizon Organic dairy products and Silk-brand soy and almond milks. The deal is valued at $300 million.
Analysts see sales-growth potential for higher-price organic products, and so far this year, investors have been keen to jump on board with new issuers tied to organic foods.
Natural- and organic-food company Annie's Inc. delivered the year's third-biggest first-day stock jump, and shares have more than doubled since the company's March IPO.
Shares of Natural Grocers by Vitamin Cottage NGVC -1.83% which operates health-food stores that sell organic products and dietary supplements, have climbed more than 40% since their July IPO.
"Institutional investors have been totally in love with big brands, especially organic," said Francis Gaskins, founder of research firm IPODesktop.com.
WhiteWave's annual sales have climbed nearly 60% over the past five years, reaching $1.9 billion in 2011. Dean's nonorganic fresh milk sales rose 24% over the same period.
Roughly four-fifths of WhiteWave's sales are from North America, and the company derives the rest from sales of soy-based beverages and food products in Europe under the Alpro and Provamel brands.
Dean Foods's longtime chairman and chief executive, Gregg Engles, will become CEO of Broomfield, Colo.'s WhiteWave. Mr. Engles will step down as Dean's CEO but remain chairman. Taking the helm at Dean will be Gregg Tanner, president of Dean's fresh dairy direct division. Dean will retain an 88% stake in WhiteWave after the offering, according to a filing with the Securities and Exchange Commission.
Last month, Dean confirmed that it is also exploring the sale of its Morningstar dairy business, the smallest of its three segments. Dean's shares have climbed nearly 50% since the offering was announced, rising more than 20% this past week. WhiteWave is scheduled to list Friday on the New York Stock Exchange under the ticker "WWAV."
Two other deals expected in the coming week are in the recently hot area of master limited partnerships, which are publicly traded entities that typically own and operate pipelines for oil and natural gas and other cash-producing assets. In recent years, MLPs' payouts, between about 6% and 7%, have been attractive to investors looking for alternatives to low-yielding bonds.
In addition to relatively high yields, MLPs are typically backed by long-term fee-based cash flows, and tend to offer stable returns that are less vulnerable to commodity-price fluctuations, said Jason Stevens, analyst at Morningstar.
Eight MLPs have come to market this year with a combined deal value of $3.3 billion, higher than any year since 2007, according to Dealogic.
The largest of the week's two MLP deals comes from MPLX LP, formed by refining company Marathon Petroleum, which is selling 15 million shares in a deal expected to raise $300 million. MPLX, based in Ohio, owns and operates a crude-oil pipeline system that stretches across the Midwest, as well as in segments of Louisiana and Texas.
MPLX's units are expected to trade on the NYSE on Friday under the ticker "MLPX."
Allentown, Pa.'s, Lehigh Gas Partners LP, formed by Lehigh Gas Corp., distributes motor fuels and leases fueling sites from Ohio to Massachusetts and is expected to sell six million units valued at $120 million. The IPO, expected Friday, will list on the NYSE under the symbol "LGP."
ALNY. Alnylam and Genzyme Form Alliance to Develop and Commercialize RNAi Therapeutics in Asia
– Genzyme to Advance ALN-TTR02 and ALN-TTRsc Programs as Breakthrough Therapies for Patients with ATTR in Japan and in the Broader Asian Market –
– Alnylam to Receive $22.5 Million in Upfront Payment in Addition to Milestone Payments and Royalties on Product Sales; Alnylam Maintains All Rights in U.S., Europe, and Rest of World –
http://finance.yahoo.com/news/alnylam-genzyme-form-alliance-develop-100000269.html
On Deck Friday. WWAV. IPO.
NasdaQ IPO info page:
http://www.nasdaq.com/markets/ipos/company/whitewave-foods-co-887169-70473
wow- that ones had a nice move friday.
from [Cjboro] INO.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=80747330
INO Inovio Pharmaceuticals sees two candidates in FierceVaccines' top 10 "promising therapeutic vaccines" list in 2012
http://www.proactiveinvestors.com/companies/news/36259/inovio-pharmaceuticals-sees-two-candidates-in-fiercevaccines-top-10-promising-therapeutic-vaccines-list-in-2012-36259.h
Inovio Pharmaceuticals sees two candidates in FierceVaccines' top 10 "promising therapeutic vaccines" list in 2012
Fri 2:19 pm by Deborah Bacal
The FierceVaccines special report spotlights 10 promising therapeutic vaccines on their way through clinical development.
Two of Inovio Pharmaceuticals' (AMEX:INO) vaccine candidates made the top ten 'promising therapeutic vaccines' list this year by newsletter FierceVaccines.
Inovio's SynCon® vaccines are designed to provide two capabilities not achievable with conventional vaccines: stimulation of T-cell immune responses to provide therapeutic capabilities, and universal cross-strain protection and treatment against known as well as newly emergent unmatched strains of pathogens. The company has clinical programs for cervical dysplasia, leukemia, the hep C virus, the flu and HIV.
For many years, vaccines were associated with the prevention of infectious diseases, but "gradually, research began to harness the activity of the immune system to prevent disease as well as treat it, starting in the field of oncology," writes FierceVaccines' Suzanne Elvidge.
One of the first therapeutic vaccines on the market - Dendreon's Provenge - gained FDA approval in 2010 for the treatment of advanced hormone-refractory prostate cancer.
After therapeutic cancer vaccines began to develop, the idea spread to virally-targeted vaccines, such as those against HIV, and HPV, which is the leading cause of cervical cancer.
The first of Inovio's candidates on the list at #4 is VGX-3100 - targeted for high risk types of HPV, or the human papillomavirus - which is behind 90 per cent or more of cervical cancer cases.
"Treating cervical cancer in its earliest stages, when doctors spot precancerous changes in the cervix, is the next target for vaccines, and Inovio Pharmaceuticals has created a DNA vaccine, VGX-3100, for this indication, which is currently in a global Phase II clinical trial," the FierceVaccine article notes.
The SynCon synthetic vaccines include a fragment of DNA that codes for an antigen, and Inovio uses electroporation--a small electric charge that loosens up the cell membrane -- to let the vaccine through.
VGX-3100 is designed to raise immune responses against the E6 and E7 oncogenes associated with HPV types 16 and 18, targeting four antigens. The idea is to stimulate a T-cell immune response strong enough to cause the rejection of the HPV-infected cells, which can turn into pre-cancerous or cancerous cells.
Recently, the company saw its stock surge after it showed for the first time that its therapeutic synthetic vaccine VGX-3100 can kill cells changed by HPV into precancerous cervical dysplasias.
The vaccine maker is now assessing the ability of its DNA-based vaccine to treat cervical dysplasias caused by HPV infection in a global phase II trial. Specifically, the study will look to determine the vaccine's ability to reverse disease progression to cervical cancer.
Results from the phase I trial appeared in a peer-reviewed journal, Science-Translational Medicine. The proof-of-concept study involed 18 women who had previously been treated for precancerous changes in the cervix, and were given Inovio's vaccine. All 18 patients showed an immune response to the vaccine, and in 78 per cent of patients, the vaccine triggered a T-cell response.
Invovio's second promising candidate on the list is PENNVAX-B, a SynCon synthetic DNA vaccine that has potential to both treat and prevent infection with HIV from clade B, the subtype of virus mostly seen in North America and Western Europe.
The vaccine is also administered with the company's CELLECTRA electroporation device, which uses a small electric pulse.
The FierceVaccines article states: "Targeting HIV infection is a huge market--according to UNAIDS, nearly 30 million people have died from HIV-related causes and roughly 34 million are living with HIV.
"While antiretroviral therapy has made a massive difference in the developed world, and the cost of the drugs has dropped, there is still a cost implication for the developing world, and market and patient access can be difficult.
"Therapeutic vaccines could be a more patient-friendly approach, with improved convenience and potentially fewer side effects."
In a phase I trial, 12 people with HIV were given four doses of the vaccine over 16 weeks, with interim results showing that the vaccine triggered a T-cell immune response to at least one antigen in 75 per cent of the people in the study.
Inovio also has a preventative and therapeutic HIV vaccine that it is developing, dubbed PENNVAX-G, which targets clades, A, C, and D that are found in developing regions of Africa and Asia.
MSG. Madison Square Garden. info-sheet.
Website. http://www.themadisonsquaregardencompany.com/
MSG Club. http://www.thegarden.com/tickets.html
iHub. No Mod. 16 posts. 3 follows.
10/11/12 Madison Square Garden Unveils Great Moments in Arena's
130+ Year History That Will be Celebrated and Commemorated in Transforme
http://ih.advfn.com/p.php?pid=nmona&article=54484446
8/24/12 Madison Square Garden 4th-Quarter Profit Soars on Sports Revenue
http://ih.advfn.com/p.php?pid=nmona&article=53936359
8/24/12 10-K
Number of shares of common stock outstanding as of July 31, 2012 :
Class A Common Stock — 62,017,285
Class B Common Stock — 13,588,555
http://ih.advfn.com/p.php?pid=nmona&article=53943731
7/12/12 LivingSocial & MadisonSquareGarden (MSG) to provide premium offers
http://www.otcmarkets.com/stock/MSG/news
7/13/12 Zacks #2 buy Enters Oversold Territory
http://ih.advfn.com/p.php?pid=nmona&article=53459223
6/26/12 Madison Square Garden Company Acquires Famed Forum Arena
http://ih.advfn.com/p.php?pid=nmona&article=52893051
6/5/12 Fuse Greenlights Three New Original Series
http://ih.advfn.com/p.php?pid=nmona&article=52662569
5/22/12 Cable Industry Look To 'Millennials' To Sustain Video Business
http://ih.advfn.com/p.php?pid=nmona&article=52517381
5/7/12 Fox Business News
MSG CEO on the Arena’s $980M Makeover [video]
http://video.foxbusiness.com/v/1678909371001/msg-ceo-on-the-arenas-980m-makeover/?playlist_id=87247
5/4/12 10-Q/3
Third quarter revenue of $400.5 million, a 21% increase compared to prior year period
Third quarter AOCF of $80.2 million, a 46% increase compared to prior year period
Third quarter operating income of $53.3 million, up 75% versus prior year period
http://ih.advfn.com/p.php?pid=nmona&article=52285799
JOEZ chart, also on my list. Watching for a new low entry. Possibly 1.04? We will see in the morning
Joe's Jeans Inc. designs, produces and sells apparel and apparel-related products to the retail and premium markets under the Joe's(R) brand and related trademarks. More information is available at the Company website at http://www.joesjeans.com
LEI chart Not a bio, but one of my watches. I am in at 1.80:)
Doji Star Bullish
In a downtrend, the market bolsters the bears with a long black day and gaps open on the second day. However, the second day trades within a small range and closes at or near its open. This scenario generally shows the potential for a rally, as many positions have been changed. Confirmation of the trend reversal would be a higher open on the next trading day
Lucas Energy, Inc., a Nevada corporation, is an independent oil and gas company based in Houston, Texas. The Company acquires underdeveloped oil and gas properties, restores production to the properties, and looks for underlying value. Currently, the Company is active in the Austin Chalk, Eagle Ford, Eaglebine, and Buda trends. Our goal for the current year is production and revenue growth, and expansion of our asset base using joint ventures.
GIVN. Given Imaging Reports New Studies Confirming Clinical Utility of Its Functional Gastrointestinal Diagnostics Products
Studies Show Value of Incorporating High Resolution Manometry in the Diagnostic Examination of Achalasia and Anorectal Disorders Expanding the Duration of pH Measurement Allows Doctors to Confidently Separate Healthy Patients From Those With Reflux
http://finance.yahoo.com/news/given-imaging-reports-studies-confirming-222426292.html
Also:
Given Imaging Announces Data at UEG Week Confirms PillCam(R) SB's Role as the Diagnostic Gold-Standard for Small Bowel Diseases
http://finance.yahoo.com/news/given-imaging-announces-data-ueg-224019174.html
Bio updates big board. StocksDiva.
http://investorshub.advfn.com/StocksDiva-Bio-Bin-16112/
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, announced today that it has received approval from the United States Food and Drug Administration (FDA) to treat high-risk aortic stenosis patients with the Edwards SAPIEN transcatheter aortic heart valve delivered both transfemorally (via the leg) and transapically (through the ribs).
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today reported net income for the quarter ended September 30, 2012 of $69.2 million, or $0.58 per diluted share, compared to net income of $51.6 million, or $0.43 per diluted share, for the same period in 2011.
Eli Lilly and Company (NYSE: LLY) and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, today announced they received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in Europe, recommending approval of Amyvid (Florbetapir F 18) solution for injection as a diagnostic radiopharmaceutical indicated for Positron Emission Tomography (PET) imaging of beta-amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer's Disease and other causes of cognitive impairment.
Given Imaging Ltd (NASDAQ: GIVN), a world leader in GI medical devices and pioneer of capsule endoscopy, today announced that investigators will present data from over 80 studies that provide new information about the benefits of using Given Imaging's products to detect, monitor and measure a range of gastrointestinal conditions at the upcoming American College of Gastroenterology (ACG) 2012 Annual Meeting taking place October 19-24, 2012 in Las Vegas, and the 20th United European Gastroenterology Week taking place October 20-24, 2012 in Amsterdam, The Netherlands.
Trius Therapeutics (NASDAQ: TSRX): Tedizolid safety data presented at IDWeek; data from Phase 3 trial indicate low incidence of adverse platelet outcomes 5.71 -0.07 : Co announced that two studies of its lead drug candidate, tedizolid phosphate, are being presented at IDWeek 2012. The first report, "A Comparative Evaluation of Adverse Platelet Outcomes among Patients with Acute Bacterial Skin and Skin Structure Infections Receiving Tedizolid Phosphate and Linezolid," summarizes the hematological results from Trius' first Phase 3 trial, ESTABLISH-1 (TR-701-112). It shows that the incidence of platelet counts below the lower limit of normal was significantly lower in patients receiving tedizolid than those treated with linezolid. Thrombocytopenia is a well-recognized toxicity signal associated with Zyvox, so this safety profile information is of particular importance for tedizolid. The second tedizolid-related report, "Population Pharmacokinetics (PK) of Oral and Intravenously Administered Tedizolid Phosphate in Adolescent Patients," evaluated the pharmacokinetics of tedizolid in adolescents. Tedizolid's high potency allows it to be administered once daily as a 200 mg oral tablet or via 200 mg IV infusion. The report concludes that the proposed adult dose of 200 mg produces tedizolid exposure in adolescents similar to healthy adults in both routes of administration.
Ziopharm Oncology (NASDAQ: ZIOP) issues statement regarding misleading blog; states 'statements made in Mr. Pearson's blog entry are misleading and wrong' 4.29 -0.33 : Co issued the following statement regarding a blog entry posted by Richard Pearson, Contributor, on Forbes.com: "The statements made in Mr. Pearson's blog entry are misleading and wrong and, given his disclosed investment position, we call into question the entire credibility of this piece. The Form 483 was issued directly to the independent investigator, not to ZIOPHARM, and had nothing to do with any outcome measures of the Phase 2 PICASSO study. All regulatory matters raised in Mr. Pearson's blog entry were resolved by the investigator in full in 2010, and had no impact on the Company's transition from Phase 2 to Phase 3. Further, the Company has no issues with drug stability. We stand by the clinical data generated at this investigator's site. Consistent with best practices, all data from ZIOPHARM's Phase 2 PICASSO study at this site were reviewed by an independent, former FDA good clinical practice auditor, and the auditor concluded that the study site's violations had no impact on the PICASSO study or the quality of data."
Savient Pharma (NASDAQ: SVNT) confirms it received a positive CHMP opinion for KRYSTEXXA approval in the EU 2.14 +0.00 : Co confirmed that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has completed its scientific assessment and has issued a positive opinion recommending approval of a marketing authorization in the European Union for KRYSTEXXA (pegloticase) for the treatment of severe debilitating chronic tophaceous gout in adult patients who may also have erosive joint involvement and who have failed to normalize serum uric acid with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these medicines are contraindicated. This opinion will be transmitted to the European Commission, which has the authority for granting marketing authorisations in the EU. If such marketing authorization is granted, KRYSTEXXA will address a significant unmet medical need for certain patients with refractory chronic gout (RCG) in the European Union.
Cleveland Biolabs (NASDAQ: CBLI) priced offering of 7.5 mln units at $2.00 per unit 2.48 : Each unit consists of one share of common stock and one warrant to purchase 0.5 shares of common stock at an exercise price of $3.00 per whole share.
BioTime (NYSE: BTX) subsidiary, LifeMap, provides update on product portfolio development; co expects to launch or upgrade its four database products during final quarter of calendar 2012 3.97 : LifeMap Sciences announced progress on key development initiatives. During the final quarter of the calendar year 2012, the company expects to launch or upgrade its four database products: GeneCards, MalaCards, PanDaTox, and LifeMap Discovery. In addition, LifeMap Sciences will launch the marketing and sales of BioTime's proprietary research product lines, including PureStem human progenitor and human embryonic stem cell lines via the company's LifeMap BioReagents portal. Another major LifeMap Sciences initiative is its therapeutic discovery collaboration with BioTime, which utilizes the LifeMap Discovery platform and leverages the LifeMap Sciences scientific team to research and identify those progenitor cell lines that are most likely to be useful in developing cell-based regenerative medicine therapies for a wide range of diseases. Once identified, selected cell lines will be marketed by LifeMap Sciences for research purposes via the LifeMap BioReagents portal and may be advanced into therapeutic development by BioTime and/or LifeMap Sciences
Novo Nordisk (NYSE: NVO) A/S: Tresiba (insulin degludec) and Ryzodeg (insulin degludec/insulin aspart) receive positive opinions from the European regulatory authorities 167.31 : Co announced that the Committee for Medicinal Products for Human Use under the European Medicines Agency (EMA) adopted positive opinions, recommending marketing authorisations, for Tresiba and Ryzodeg for the treatment of diabetes mellitus in adults.
Tresiba, the intended brand name for insulin degludec, is a new generation of once-daily basal insulin. In 'treat-to-target' studies supporting the new drug application, where Tresiba was compared to insulin glargine, Tresiba demonstrated a significantly lower risk of overall and nocturnal hypoglycaemia, while successfully achieving equivalent reductions in HbA1c. Further, with a duration of action beyond 42 hours, Tresiba is the first basal insulin to offer patients the possibility of adjusting the time of injection, when needed.
Nabi Biopharmaceuticals (NASDAQ: NABI) announces exchange ratio for proposed business combination transaction with Biota Holdings Limited 1.80 : Co announced that, if the proposed business combination transaction between Nabi Biopharmaceuticals (NABI) and Biota Holdings Limited (ASX:BTA.AX) is completed, each ordinary share of Biota capital stock will be transferred to Nabi in exchange for 0.749778075 of a share of Nabi common stock, subject to the adjustment described below if the proposed reverse stock split becomes effective. If the proposed reverse stock split is approved by Nabi stockholders at the reconvened special meeting of stockholders to be held Oct 22, 2012, depending on the ratio for the reverse stock split determined by Nabi's board of directors, four, five, six, seven or eight shares of existing Nabi common stock will be combined into one new share of Nabi common stock.
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, announced it has received approval from the US FDA to treat high-risk aortic stenosis patients with the Edwards SAPIEN transcatheter aortic heart valve delivered both transfemorally (via the leg) and transapically (through the ribs). With the addition of high-risk patients to those eligible for the transcatheter procedure and with the approval of the transapical approach, a considerably broader group can now be treated with the SAPIEN valve. Previously, SAPIEN was approved in the U.S. only for the treatment of inoperable patients via the transfemoral approach.
"We are thankful to the multidisciplinary Heart Teams who worked diligently throughout The PARTNER Trial to bring new treatments to U.S. patients at high risk for surgical aortic valve replacement," said Larry L. Wood, Edwards' corporate vice president, transcatheter heart valves. "It is extremely rewarding for us and our clinical partners to know that high-risk patients suffering from this often debilitating disease will now have access to this life-saving therapy."
About Transcatheter Aortic Valve Replacement (TAVR) In performing the TAVR procedure, the valve is crimped onto the catheter-based delivery system and inserted into the body in one of two ways: transfemorally or transapically. Once delivered to the site of the patient's diseased valve, the SAPIEN valve is expanded with a balloon and immediately functions in place of the patient's native aortic valve.
The Edwards SAPIEN valve is indicated for the treatment of patients with severe symptomatic calcified native aortic valve stenosis who have been examined by a Heart Team, including an experienced cardiac surgeon and a cardiologist, and found to be inoperable or at high risk for traditional open heart surgery, and in whom existing co-morbidities would not preclude the expected benefit from the procedure. The previous FDA approval for the treatment of inoperable patients was granted on Nov. 2, 2011.
Abbott (NYSE: ABT) announced the European Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for HUMIRA® (adalimumab) for the treatment of pediatric patients aged six to 17 years with severely active Crohn's disease (CD) who failed, are intolerant to or have contraindications to conventional therapy. Following the CHMP's positive opinion, a final decision from the European Commission is anticipated in the next several weeks. Upon final decision, HUMIRA will be the only biologic in the European Union (EU) for the treatment of pediatric CD offering at-home administration.
Pediatric CD is a chronic, debilitating condition of the gastrointestinal (GI) tract that affects up to 200,000 children worldwide(i,ii) CD most commonly involves the end of the small intestine and the beginning of the large intestine.(iii) In addition to symptoms such as chronic abdominal pain, weight loss and loose stools(i) pediatric CD can affect children in several ways, including potentially contributing to malnutrition, failure to grow and/or delayed puberty.(i,iv)
thanks you too!
Thanks carp1. I was a mod there till I had to cut back.
I will support that board.
Nice list my friend!!!
Have a great weekend glassy.
I played SATC too but did not hold it. I am holding AONE
EW. 3:12pm FDA Approves Expanded Indication for Edwards Lifesciences' Transcatheter Valve
http://finance.yahoo.com/news/fda-approves-expanded-indication-edwards-191143626.html
'Nooner' iBoxed.
Followers
|
7
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
564
|
Created
|
09/23/12
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |